Business Context and Reporting Period
This Form 8-K Current Report was filed by NeuroOne Medical Technologies Corp on April 3, 2026. The filing primarily reports on the results of the Company's Annual Meeting of Stockholders held on the same date and details amendments to the Company's equity incentive plan.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions and stockholder voting results.
Material Changes and Corporate Actions
The following material actions were approved by stockholders at the Annual Meeting:
- Reverse Stock Split Authorization: Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split of outstanding common stock at a ratio between 1-for-2 and 1-for-15, to be determined by the Board of Directors.
- Equity Plan Amendment: Stockholders approved an amendment to the 2025 Equity Incentive Plan to:
- Increase the aggregate number of shares available for issuance by 1,500,000 new shares.
- Implement an automatic annual increase of 5% of Fully Diluted Shares for five years (2027–2031), subject to Board discretion to reduce the amount.
- Board Elections: Two Class III directors, Jeffrey Mathiesen and Edward Andrle, were elected to serve three-year terms until 2029.
- Auditor Ratification: Baker Tilly US, LLP was ratified as the independent registered public accounting firm for the fiscal year ending September 30, 2026.
Voting Results Summary
A total of 30,272,834 shares (approximately 59.72% of outstanding shares) were present at the meeting. Key voting outcomes include:
| Proposal | Votes For | Votes Against | Abstain / Withheld |
|---|---|---|---|
| Election of Directors (Class III) | 18,384,823 (Mathiesen) 18,174,404 (Andrle) |
N/A | 494,745 (Mathiesen) 705,164 (Andrle) |
| Ratification of Auditor | 30,031,054 | 70,706 | 171,074 |
| Reverse Stock Split (1-for-2 to 1-for-15) | 28,408,499 | 1,780,031 | 84,304 |
| Equity Incentive Plan Amendment | 15,146,194 | 3,415,319 | 318,056 |
| Adjournment Authorization | 29,020,938 | 1,067,842 | 184,052 |
Outlook, Risks, and Contingencies
The filing does not provide specific management commentary on future financial outlook, risks, or contingencies beyond the authorization of the reverse stock split. The Board retains discretion to determine the specific split ratio within the approved range (1-for-2 to 1-for-15).
Key Facts for Investor Verification
- Verify the specific reverse stock split ratio once determined by the Board, as this will impact share count and price per share.
- Monitor the implementation timeline for the 1,500,000 share increase to the equity plan and the commencement of the annual 5% automatic increases in 2027.
- Review the definitive proxy statement filed on March 9, 2026, for detailed biographies of the newly elected directors and further context on the equity plan amendments.
- Note that approximately 40.28% of outstanding shares were not represented at the meeting.